Replies to post #96862 on Biotech Values

[iwfal]

Resistance to T -

Unless they do not compensate by additional mutation/s that restore replicative replication efficiency, then after termination of antiviral therapy they no longer have any advantage and are replaced by lower resistant variants and WT. So I don't think that relapse requires that the virus become at least low level resistant.

Thus you are suggesting relapsed patients are relapse because they develop high level resistant strains of HCV that then mutate to be low level resistance strains once the treatment stops - i.e. the low level resistance strains are what drive the relapse, but only because high level resistance prevented the HCV from being wiped out during treatment?